Clinical trialNCT07454382RecruitingPhase 2Interventional

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment26Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alexander Lesokhin, MD
Memorial Sloan Kettering Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (all Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (all Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (all Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (all Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (limited Protocol Activities)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Elranatamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Feb 2026
Primary completion: 27 Aug 2029
Completion: 27 Aug 2029
Last update posted: 16 Jun 2026
Registered enrollment: 26
Registry id: NCT07454382

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.